Paclitaxel, ifosfamide, and cisplatin as initial salvage chemotherapy for germ cell tumors: Long-term follow-up and outcomes for favorable- and unfavorable-risk disease

Loading...
Thumbnail Image
Files
Date
2024-07-19
Authors
Gleeson, Jack P.
Knezevic, Andrea
Bromberg, Maria
Patil, Sujata
Sheinfeld, Joel
Carver, Brett S.
Bains, Manjit
Jones, David R.
Bajorin, Dean F.
Bosl, George J.
Journal Title
Journal ISSN
Volume Title
Publisher
American Society of Clinical Oncology
Research Projects
Organizational Units
Journal Issue
Abstract
Purpose: Paclitaxel, ifosfamide, and cisplatin (TIP) is an established salvage regimen for germ cell tumors (GCT) on the basis of a phase II trial, but efficacy on a large patient cohort including patients with unfavorable risk features and long-term outcomes has not been reported. Herein, we report updated treatment efficacy and long-term follow-up with TIP. Patients and Methods: Patients with GCT who received TIP after cisplatin-based chemotherapy were eligible. Favorable response (complete response or partial response with negative tumor markers), overall survival (OS) and progression-free survival (PFS) rates, relapse, and toxicity were determined. Disease was reclassified according to the International Prognostic Factor Study Group (IPFSG) score. Results: Of the 104 patients, 87 had favorable risk factors and 17 had at least one unfavorable factor by Memorial Sloan Kettering Cancer Center (MSKCC) criteria. Ten patients were treated for a second gonadal primary GCT. With a median follow-up of 8.9 years, the 5-year PFS and OS rates were 66% (95% CI, 55 to 74) and 69% (95% CI, 59 to 77), respectively. Among 87 patients with favorable-risk disease, 69 (79%) achieved a favorable response with 5-year PFS and OS rates of 67% (95% CI, 56 to 76) and 72% (95% CI, 61 to 80), respectively. Among 17 patients with MSKCC unfavorable-risk disease, 13 (76%) achieved a favorable response with 5-year PFS and OS rates of 59% (95% CI, 33 to 78) and 56% (95% CI, 28 to 76), respectively. After IPFSG reclassification, 5-year PFS and OS rates for patients with ≤intermediate-risk disease were 75% (95% CI, 50 to 89) and 73% (95% CI, 55 to 85), respectively. Conclusion: TIP is an effective second-line regimen for patients with GCT. Similar outcomes were observed in patients with favorable- and unfavorable-risk disease. The randomized TIGER trial (ClinicalTrials.gov identifier: NCT02375204) comparing TIP with high-dose chemotherapy will determine the optimal second-line treatment approach.
Description
Keywords
Paclitaxel, ifosfamide, and cisplatin (TIP) , Salvage regimen , Germ cell tumors (GCT) , Large patient cohort , Unfavorable risk features , Long-term outcomes
Citation
Gleeson, J. P., Knezevic, A., Bromberg, M., Patil, S., Sheinfeld, J., Carver, B. S., Bains, M., Jones, D. R., Bajorin, D. F., Bosl, G. J., McHugh, D. J., Funt, S. A., Motzer, R. J. and Feldman, D. R. (2024) 'Paclitaxel, ifosfamide, and cisplatin as initial salvage chemotherapy for germ cell tumors: Long-term follow-up and outcomes for favorable- and unfavorable-risk disease', Journal of Clinical Oncology. https://doi.org/10.1200/JCO.23.02542
Link to publisher’s version
Copyright
© 2024, American Society of Clinical Oncology.